Compare AstraZeneca plc (AZN) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Kinross Gold Corporation — how do they compare? AstraZeneca plc trades at $166.43 (market cap $253.13B), while Kinross Gold Corporation trades at $23.91 (market cap $28.24B). The key difference: AstraZeneca plc is far larger — about 9× Kinross Gold Corporation's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | KGC | |
|---|---|---|
Market Cap | $253.13B | $28.24B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $38.06 |
52-Week Low | $137.44 | $15.33 |
Enterprise Value | $279.37B | $26.80B |
Dividend Yield | 1.92% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
KGC trades at $23.48, down 2.73% on the day, amid a bearish technical signal. Fundamentally, the company shows robust health with revenue growth from $3.5B in 2022 to $7.05B in 2025 and a net income margin of 35.99%. Recent quarters have consistently beaten EPS estimates. Analyst consensus is bullish with a $37.20 price target, though technical indicators suggest near-term pressure.
The outlook for KGC is positive based on strong fundamentals and growth trajectory, but investors face near-term technical headwinds and sensitivity to gold prices. The stock presents a value opportunity with a low P/E of 9.99, though execution on production guidance and cost management remain key to realizing upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
